BioLineRx Ltd. (TLV:BLRX)

Market Cap	39.16M -23.7%
Revenue (ttm)	42.17M -42.1%
Net Income	-9.86M
EPS	-0.00
Shares Out	2.61B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,615,292
Average Volume	3,167,401
Open	1.500
Previous Close	1.500
Day's Range	1.500 - 1.500
52-Week Range	1.400 - 3.900
Beta	0.46
RSI	51.09
Earnings Date	Mar 31, 2026

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company’s pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin les...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 28
• Stock Exchange: Tel Aviv Stock Exchange
• Ticker Symbol: BLRX

Financial Performance

In 2024, BioLineRx's revenue was $28.94 million, an increase of 502.92% compared to the previous year's $4.80 million. Losses were -$9.22 million, -84.79% less than in 2023.

Financial numbers in USD